Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · IEX Real-Time Price · USD
22.01
-0.59 (-2.61%)
At close: Jul 19, 2024, 4:00 PM
21.90
-0.11 (-0.50%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
The company is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Samuel S. Kintz M.B.A. |
Contact Details
Address: 6200 Lookout Road Boulder, Colorado 80301 United States | |
| Phone | 720-647-8519 |
| Website | enliventherapeutics.com |
Stock Details
| Ticker Symbol | ELVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001672619 |
| CUSIP Number | 29337E102 |
| ISIN Number | US29337E1029 |
| Employer ID | 81-1523849 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Samuel S. Kintz M.B.A. | Co-Founder, Chief Executive Officer, Secretary and Director |
| Benjamin Hohl | Chief Financial Officer and Head of Corporate Development |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder, Chief Scientific Officer and Directors |
| Anish Patel Pharm.D. | Co-Founder and Chief Operating Officer |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | 144 | Filing |
| Jul 12, 2024 | 144 | Filing |
| Jul 12, 2024 | 144 | Filing |
| Jul 1, 2024 | 144 | Filing |
| Jun 27, 2024 | 144 | Filing |
| Jun 25, 2024 | 144 | Filing |
| Jun 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 18, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 144 | Filing |
| May 29, 2024 | 144 | Filing |